Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) is a progressive disease isolated to the lung. IPF is a type of interstitial lung disease, which is a group of 200 diseases with similar symptoms but different causes. Symptoms of Idiopathic pulmonary fibrosis develop gradually and may not be noticed until the disease is well-established. IPF affects each person differently and the disease progresses at varying rates and it primarily involves the interstitium (the tissue and space around the air sacs of the lungs) and does not affect the airways or blood vessels directly.
Related Conference of Idiopathic Pulmonary Fibrosis
September 23-24, 2024
15th International Conference on Pulmonary & Respiratory Medicine
Singapore City, Singapore
October 24-25, 2024
4th International Conference on Tuberculosis, Lung Health and Respiratory Diseases
Paris, France
Idiopathic Pulmonary Fibrosis Conference Speakers
Recommended Sessions
- Asthma
- Chronic Obstructive Pulmonary Disease
- Alpha 1 Antitrypsin Deficiency & COPD
- Cardiopulmonary Disorders
- Clinical management of severe acute respiratory infection
- COVID-19 Treatment and Recovery
- Covid19 Vaccine and Lung Immunopathology
- Cystic Fibrosis
- Depression and anxiety in COPD
- Diagnosis and Treatment of COPD
- Digital Health in Respiratory Care
- Effect of COVID-19 on Lungs
- Genetic risk factor of COPD
- Idiopathic Pulmonary Fibrosis
- Innate Immunity and Lung Fibrosis
- Investigational Drugs and Other Therapies in the treatment of Respiratory Disease
- Lung cancer
- Lung Cancer Diagnosis & Treatment
- Pathology and Clinical Management of COPD
- Pneumonia
- Pulmonary Rehabilitation
- Respiratory Diseases
- Severe Acute Respiratory Syndrome (SARS)
- Sleep apnea
- Tuberculosis
Related Journals
Are you interested in
- Advancements in Pulmonary Diagnostics - Respiratory 2024 (France)
- Asthma - Tuberculosis-2024 (France)
- Atelectasis and Pneumothorax - Tuberculosis-2024 (France)
- Cardio Pulmonary Disorders - Respiratory 2024 (France)
- Cardiopulmonary Disease - Tuberculosis-2024 (France)
- Chronic Obstructive Pulmonary Disease - Respiratory 2024 (France)
- Chronic Obstructive Pulmonary Disease (COPD) - Tuberculosis-2024 (France)
- Climate Change and Respiratory Diseases - Tuberculosis-2024 (France)
- COVID-19 and Asthma - Respiratory 2024 (France)
- COVID-19 and Respiratory System - Respiratory 2024 (France)
- Epidemiology of TB Disease - Tuberculosis-2024 (France)
- Gastroesophageal reflux disease (GERD) - Tuberculosis-2024 (France)
- Idiopathic Pulmonary Fibrosis - Respiratory 2024 (France)
- Interstitial Lung Disease - Respiratory 2024 (France)
- Latent TB Infection and Active TB Disease - Tuberculosis-2024 (France)
- Lung Cancer - Respiratory 2024 (France)
- Lung Cancer: Screening, Diagnosis & Treatment - Tuberculosis-2024 (France)
- Lung Function in Men with and without HIV - Tuberculosis-2024 (France)
- Lung Infection - Tuberculosis-2024 (France)
- Lung Transplantation - Respiratory 2024 (France)
- Multidrug-resistant TB - Tuberculosis-2024 (France)
- Mycobacterial Infections - Tuberculosis-2024 (France)
- Obstructive Sleep Apnea - Respiratory 2024 (France)
- Occupational Lung Diseases - Respiratory 2024 (France)
- Palliative Care for Advanced Lung Cancer - Tuberculosis-2024 (France)
- Pneumonia - Respiratory 2024 (France)
- Pulmonary Complications of Endocrine Diseases - Tuberculosis-2024 (France)
- Pulmonary Diseases and Therapeutics - Tuberculosis-2024 (France)
- Pulmonary diseases: Treatment, Diagnosis and therapies - Respiratory 2024 (France)
- Pulmonary Edema - Tuberculosis-2024 (France)
- Pulmonary Hypertension - Respiratory 2024 (France)
- Pulmonary Rehabilitation - Respiratory 2024 (France)
- TB Clinical Trials - Tuberculosis-2024 (France)
- TB Diagnosis, Prevention & Treatment - Tuberculosis-2024 (France)
- TB Vaccines - Tuberculosis-2024 (France)
- TB-HIV Co-infections - Tuberculosis-2024 (France)
- Tuberculosis - Respiratory 2024 (France)
- Zoonotic TB - Tuberculosis-2024 (France)